Iricryn (Bimatoprost)

Bimatoprost acts as an agonist at the prostaglandin F (FP) receptors in the eye’s ciliary body. Activation of these receptors enhances the uveoscleral outflow of aqueous humor, which reduces intraocular pressure. In hair follicles, the same receptor stimulation promotes the growth phase of eyelashes, resulting in increased length, thickness, and pigmentation.

The dosing regimen for Iricryn is determined by the prescribing ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing are individualized based on the patient’s condition, response, and tolerance. Patients should follow the prescriber’s instructions precisely.

Bimatoprost is classified as pregnancy category C, indicating that risk cannot be ruled out and it should only be used if the potential benefit justifies the potential fetal risk. Limited data are available for breastfeeding; therefore, caution is advised and the prescriber should evaluate the risk‑benefit ratio before use.

To request Iricryn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The team then provides pricing, availability, shipping details and any necessary import documentation.

Iricryn (bimatoprost) belongs to the prostaglandin analog class, which generally offers once‑daily dosing and potent intraocular pressure reduction. Compared with beta‑blocker drops, prostaglandin analogues often have a better tolerability profile and greater efficacy in many patients, though individual response varies and choice depends on clinical factors and patient preference.

Iricryn should be stored at room temperature, below 25 °C, in the original container. Keep the bottle tightly closed, protect it from light and moisture, and avoid freezing. Do not refrigerate unless otherwise directed by the pharmacist. Discard any solution that appears discolored or contains particles.

Iricryn is applied as an ophthalmic solution. The patient should wash hands, tilt the head back, and gently pull down the lower eyelid to create a pocket. One drop is placed into the conjunctival sac of the prescribed eye(s) without touching the tip to the eye or lashes. The eye should be closed gently for a few minutes to aid absorption.

Although uncommon, serious adverse events can include severe ocular inflammation such as iridocyclitis, significant conjunctival hyperemia, periorbital skin darkening, macular edema, and vision loss. Patients should seek immediate medical attention if they experience eye pain, worsening redness, sudden vision changes, or signs of an allergic reaction such as swelling or difficulty breathing.

Iricryn is contraindicated in patients with active intraocular inflammation, such as uveitis or iritis, and in those who have demonstrated hypersensitivity to bimatoprost or any component of the formulation. Caution is also advised for individuals with a history of severe ocular side effects, pregnant women unless clearly needed, and patients using certain interacting ocular medications. The prescriber should assess suitability before initiating therapy.